E-ISSN 2146-9369 | ISSN 2146-3158
 
2024, Vol: 14, Issue: 4
14 / 4Current Issue ArchiveAims and ScopeAbstracting & IndexingMost Accessed ArticlesMost Downloaded ArticlesMost Cited Articles

Research Article 


Clinical profile of patients treated with cefepime/tazobactam: A new ß-lactam-ß-lactamase inhibitor combination

Abdul Ghafur, Ashwini Tayade, Priyadarshini Kannaian.


Cited By:24

Abstract
Background and Purpose: Cefepime-tazobactam is a new ß-lactam ß-lactamase inhibitor combination licensed for clinical use by Drugs Controller General of India. Aim of our study was to analyze the clinical efficacy and safety of cefepime-tazobactam in patients with sepsis. To the best of our knowledge, this is the first published clinical study on this drug. Materials and Methods: A retrospective observational study on the efficacy and safety of cefepime-tazobactam was conducted at tertiary care hospital, South India. Patients who had a clear source of infection, having a single organism as the causative agent and being treated with cefepime-tazobactam alone were analyzed for efficacy and those cases who had a clear source of infection but either had multiple organism grown or cultures being negative or those patients who received a combination of antibiotics were analyzed for the safety analysis. Results: Thirty two patients satisfied our study criteria. All 15 patients in the efficacy group (nine with ventilator associated pneumonia, three tracheitis, two bacteraemia and one with urosepsis) had complete clinical cure, with microbiological cure in cases where a repeat culture was indicated. There were no significant side effects in any of the evaluable 32 patients assessed for safety. Conclusion: Cefepime-tazobactam is a safe and effective agent to treat patients with nonlife threatening sepsis due to Gram negative bacteria.


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Abdul Ghafur
Articles by Ashwini Tayade
Articles by Priyadarshini Kannaian
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Ghafur A, Tayade A, Kannaian P. Clinical profile of patients treated with cefepime/tazobactam: A new ß-lactam-ß-lactamase inhibitor combination. J Microbiol Infect Dis. 2012; 2(3): 79-86 . doi:10.5799/jmid2012.03.0049

Web Style

Ghafur A, Tayade A, Kannaian P. Clinical profile of patients treated with cefepime/tazobactam: A new ß-lactam-ß-lactamase inhibitor combination. https://www.jmidonline.org/?mno=302656944 [Access: January 09, 2025]. doi:10.5799/jmid2012.03.0049

AMA (American Medical Association) Style

Ghafur A, Tayade A, Kannaian P. Clinical profile of patients treated with cefepime/tazobactam: A new ß-lactam-ß-lactamase inhibitor combination. J Microbiol Infect Dis. 2012; 2(3): 79-86 . doi:10.5799/jmid2012.03.0049


Vancouver/ICMJE Style

Ghafur A, Tayade A, Kannaian P. Clinical profile of patients treated with cefepime/tazobactam: A new ß-lactam-ß-lactamase inhibitor combination. J Microbiol Infect Dis. (2012), [cited January 09, 2025]; 2(3): 79-86 . doi:10.5799/jmid2012.03.0049


Harvard Style

Ghafur, A., Tayade, . A. & Kannaian, . P. (2012) Clinical profile of patients treated with cefepime/tazobactam: A new ß-lactam-ß-lactamase inhibitor combination. J Microbiol Infect Dis, 2 (3), 79-86 . doi:10.5799/jmid2012.03.0049


Turabian Style

Ghafur, Abdul, Ashwini Tayade, and Priyadarshini Kannaian. 2012. Clinical profile of patients treated with cefepime/tazobactam: A new ß-lactam-ß-lactamase inhibitor combination. Journal of Microbiology and Infectious Diseases, 2 (3), 79-86 . doi:10.5799/jmid2012.03.0049


Chicago Style

Ghafur, Abdul, Ashwini Tayade, and Priyadarshini Kannaian. "Clinical profile of patients treated with cefepime/tazobactam: A new ß-lactam-ß-lactamase inhibitor combination." Journal of Microbiology and Infectious Diseases 2 (2012), 79-86 . doi:10.5799/jmid2012.03.0049


MLA (The Modern Language Association) Style

Ghafur, Abdul, Ashwini Tayade, and Priyadarshini Kannaian. "Clinical profile of patients treated with cefepime/tazobactam: A new ß-lactam-ß-lactamase inhibitor combination." Journal of Microbiology and Infectious Diseases 2.3 (2012), 79-86 . Print. doi:10.5799/jmid2012.03.0049


APA (American Psychological Association) Style

Ghafur, A., Tayade, . A. & Kannaian, . P. (2012) Clinical profile of patients treated with cefepime/tazobactam: A new ß-lactam-ß-lactamase inhibitor combination. Journal of Microbiology and Infectious Diseases, 2 (3), 79-86 . doi:10.5799/jmid2012.03.0049


Author LoginReviewer LoginAbout PublisherOpen Access PolicyEditorial PoliciesPeer Review PolicyPublication Ethics and Publication Malpractice StatementConflict of Interest PolicyPlagiarism PolicyProtection of Research Participants (Statement On Human And Animal Rights)Privacy PolicyCorrections, Retractions & Expressions of ConcernSelf-Archiving PoliciesDigital Archiving & Preservation PoliciesStatement of Informed ConsentAdvertising PolicyTerms of UseLicense InformationCopyright Information

About Journal of Microbiology and Infectious Diseases

Journal of Microbiology and Infectious Diseases (JMID) is an international "peer review" journal in microbiology, infectious diseases, virology, ... Read more.



For best results, please use Internet Explorer or Google Chrome.

Contact Information

All correspondence should be addressed to:

Prof. Ibrahim Eldaghayes

Editor-in-Chief

Journal of Microbiology and Infectious Diseases

Department of Microbiology and Parasitology 

Faculty of Veterinary Medicine

University of Tripoli

P.O. Box 13662, Tripoli, Libya